STAT

Opinion: Long-acting medications for opioid addiction help patients control their future, unreliable selves

Effective medications that stay active in the body for weeks or months can help people addicted to opioids parlay transitory desires to stop using these drugs into lasting recovery from…
A patient takes buprenorphine as part of a medication-assisted therapy program in Imphal, India.

When my patient, Marcus, wakes up shaky, exhausted, and ashamed each morning, he wants to quit using heroin more than anything else in the world. But that’s not the Marcus who is making decisions a few hours later.

Like countless people with addictions I have met in my career as a clinician and researcher, Marcus (not his real name) makes repeated, sincere resolutions to stop his drug use only to have his future self return to it a month, a week, a day, even an hour

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Wegovy And Ozempic Sales, Rising Pharma Layoffs, And More
Sales of the blockbuster Wegovy obesity treatment more than doubled in the first quarter as Novo Nordisk races to make more of the drug to meet surging demand.
STAT2 min readAmerican Government
STAT+: Pharmalittle: We’re Reading About FTC Reviewing Novo-Catalent Deal, Amneal Opioid Settlement, And More
The FTC wants more information on a $16.5 million deal in which Novo Nordisk's parent company would purchase Catalent, a contract drug manufacturer.

Related Books & Audiobooks